Latest news with #GRIN
Yahoo
21-07-2025
- Business
- Yahoo
Grown Rogue to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025
MEDFORD, Ore., July 21, 2025 /CNW/ - Grown Rogue International Inc. ("Grown Rogue" or the "Company") (CSE: GRIN) (OTC: GRUSF), a flower-forward cannabis company combining craft values with disciplined execution, will report its financial results for the second quarter ended June 30, 2025, on Tuesday, August 12, 2025, after market close. The Company will also host a conference call on Tuesday, August 12, 2025, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the results and provide a corporate update. CEO Obie Strickler and members of the management team will host the call, followed by a question-and-answer period. Conference Call Details Date: Tuesday August 12, 2025 Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) Webcast: Register Dial-in: 1-800-836-8184 (North America Toll-Free) 1-800-836-8184 (Canada Toll-Free) A telephone replay of the conference call will be available until 19 August 2025, by dialing (+1) 888 660 6345 and using replay code: 33641# The webcast will be archived on Grown Rogue's Investor Relations website for approximately 90 days following the call. For assistance, please contact: invest@ About Grown Rogue Grown Rogue International Inc. (CSE: GRIN | OTC: GRUSF) is a flower-forward cannabis company rooted in Oregon's Rogue Valley, a region known for its deep cannabis heritage and commitment to quality. With operations in Oregon, Michigan, and New Jersey—and expansion underway in Illinois— Grown Rogue specializes in producing designer-quality indoor flower. Known for exceptional consistency and care in cultivation, our products are valued by retailers, budtenders, and consumers alike. By blending craft values with disciplined execution, we've built a scalable, capital-efficient platform designed to thrive in competitive markets. We believe sustained excellence in cannabis flower production is the engine of the industry's supply chain—and our competitive advantage. For more information about Grown Rogue, please visit SOURCE Grown Rogue International Inc. View original content to download multimedia: Sign in to access your portfolio
Business Wire
26-06-2025
- Business
- Business Wire
Victory Capital Expands VictoryShares ® Offerings with Three New ETFs
SAN ANTONIO--(BUSINESS WIRE)--Victory Capital Holdings, Inc. (NASDAQ: VCTR) ('Victory Capital' or the 'Company') today announced that its wholly owned investment adviser, Victory Capital Management Inc., has launched three new exchange-traded funds (ETFs), VictoryShares Pioneer Asset-Based Income ETF (ABI), VictoryShares International Free Cash Flow ETF (IFLO), and VictoryShares International Free Cash Flow Growth ETF (GRIN). Victory Capital Management Inc., has launched 3 new exchange-traded funds (ETFs), VictoryShares Pioneer Asset-Based Income ETF (ABI), VictoryShares International Free Cash Flow ETF (IFLO), and VictoryShares International Free Cash Flow Growth ETF (GRIN) The launch of ABI marks a significant milestone as the first strategy from Pioneer Investments, Victory Capital's newest Investment Franchise, to be offered in an ETF wrapper. The strategy is designed to capture premium yields available within select subsets of the securitized credit markets. 'ABI, actively managed by Pioneer Investments, provides access to asset-based income that takes advantage of the same secular trends driving private credit markets with the benefits of an ETF,' said Mannik Dhillon, CFA ®, CAIA ®, President, Investment Franchises and Solutions for Victory Capital. 'ABI offers investors private-credit-like characteristics in a listed ETF with inherent liquidity features.' ABI aims to deliver a differentiated income stream by investing in specialized fixed income sectors, including those that bridge the public and private credit markets. The strategy targets non-benchmark securities collateralized by physical assets, as well as securities with cash flows connected to diverse non-bank lending channels. By targeting credit exposures in these areas, ABI seeks to provide an attractive total return primarily through high current income with low correlations to traditional fixed income. 'Industry professionals have increasingly recognized the potential for private credit to offer attractive income with low correlations, and many believe asset-based finance is the next frontier,' said Marco Pirondini, Chief Investment Officer at Pioneer Investments. 'We are excited to bring our team's conviction-driven, active management approach to our clients in an ETF.' IFLO and GRIN provide investors an opportunity to build globally diversified free cash flow (FCF) driven portfolios when combined with other FCF ETFs from VictoryShares. The ETFs become the fourth and fifth strategies in the Company's next generation FCF suite and utilize the same disciplined rules-based index methodology as Victory Capital's existing FCF ETFs, while offering investors exposure to developed international markets. The VictoryShares ETF platform now stands at 26 ETFs with the addition of these new funds and highlights Victory Capital's commitment to introducing innovative ETFs designed to meet client needs. The Company's ETF platform has grown to more than $14 billion in AUM as of May 31, 2025. About Victory Capital Victory Capital is a diversified global asset management firm with $293.1 billion in total client assets as of May 31, 2025. The Company employs a next-generation business strategy that combines boutique investment qualities with the benefits of a fully integrated, centralized operating and distribution platform. Victory Capital provides specialized investment strategies to institutions, intermediaries, retirement platforms and individual investors. With 12 autonomous Investment Franchises and a Solutions Business, Victory Capital offers a wide array of investment products, including mutual funds, ETFs, separately managed accounts, alternative investments, third-party ETF model strategies, collective investment trusts, private funds, a 529 Education Savings Plan, and brokerage services. Victory Capital is headquartered in San Antonio, Texas, with offices and investment professionals in the U.S. and around the world. To learn more please visit or follow Victory Capital on Facebook, Twitter, and LinkedIn. Carefully consider a fund's investment objectives, risks, charges and expenses before investing. To obtain a prospectus or summary prospectus containing this and other important information, visit Read it carefully before investing. All investing involves risk, including the potential loss of principal. ETFs have the same risks as the underlying securities traded on the exchange throughout the day. ETFs may trade at a premium or discount to their net asset value. Redemptions are limited and commissions are often charged on each trade. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles or from economic or political instability in other nations. The Funds are new and, therefore, have limited operations histories for investors to evaluate. Large shareholders, including other funds advised by the Adviser, may own a substantial amount of each Fund's shares. The actions of large shareholders, including large inflows or outflows, may adversely affect other shareholders, including potentially increasing capital gains. The value of your investment is also subject to geopolitical risks such as wars, terrorism, trade disputes, environmental disasters, and public health crises; the risk of technology malfunctions or disruptions; and the responses to such events by governments and/or individual companies. IFLO and GRIN are Index Funds, which invest in securities included in, or representative of securities included in, the Index, regardless of their investment merits. The performance of the funds may diverge from that of the Index. Investing in companies with high free cash flows could lead to underperformance when such investments are unpopular or during periods of industry disruptions. The funds could also be affected by company-specific factors that could jeopardize the generation of free cash flow. The debt instruments in which ABI invests are subject to interest rate, inflation, credit and default risk. When interest rates rise, the prices of fixed-income securities will generally fall and vice versa. Credit risk refers to the possibility that debt issuers may not be able to make principal and interest payments or may have their debt downgraded by ratings agencies. High yield securities (also known as 'junk bonds') may be more volatile, subject to greater levels of credit or default risk, less liquid and more difficult to sell at an advantageous time or price than higher-rated securities of similar maturity. Privately issued loans involve greater risk than those of traditional lenders due to higher levels of credit risk and, because they are not traded on established markets, difficult to value and potentially less liquid. Inflation-protected bonds typically have lower yields than conventional fixed rate bonds and will likely decline in price during periods of deflation, which could result in losses. Mortgage-backed securities ("MBS") and asset-backed securities ("ABS") are subject to credit, prepayment (where the issuer may repay a bond earlier than expected) and extension risk (where the issuer may repay a bond more slowly than expected) and may react differently to changes in interest rates than other bonds. Small movements in interest rates may quickly and significantly reduce the value of certain MBS and ABS. There may be limited public information available regarding the floating rate loans in which the fund invests; they may be difficult to value and may be illiquid, meaning that the Adviser may not be able to sell them at an advantageous time or price, which may adversely affect the Fund. In unusual or adverse markets, floating rate loans may have higher than normal default rates. In periods of recession, the Fund's investments in floating rate loans are more likely to decline. The values of floating rate securities generally are less sensitive to changes in interest rates but may decline in value if their rates are not adjusted as much, or as quickly, as prevailing interest rates. The Fund may invest in insurance-linked securities (ILS). Should a trigger event occur that leads to physical or economic loss, the Fund could lose all or part of its principal investment, and the right to interest or dividend payments. ILS are also subject to credit, default and liquidity risk. Derivatives may not work as intended and may result in losses. VictoryShares ETFs are distributed by Victory Capital Services, Inc. (VCS), an affiliate of Victory Capital Management Inc., the Funds' adviser.
Daily Mail
21-04-2025
- Business
- Daily Mail
Beauty experts reveal the biggest recession indicator trends, from DIY extensions to spray tans
Experts have noted signs that a recession is coming, whether it's people spending less money at strip clubs or Americans falling behind on car payments at record rates. There are fashion and beauty signs that only Gen Z and millennial women have spotted indicating an upcoming economic downturn. Some women have noted that clothing seems to be cheaper and coal mining inspired, comparing it to what characters wore in District 12 in The Hunger Games, which was inspired by Appalachia. Others have noticed that more low-key hairstyles that don't require expensive products and upkeep are on the rise, including natural, frizzy hair. Now, Megan Vasquez, a beauty influencer marketing expert at GRIN, has pointed out multiple indications that Gen Z and millennial women are preparing for an economic downtick. Megan, based in Los Angeles, has found that 'people are stretching time between salon visits with lower maintenance options.' 'When areas of life feel uncertain or restricted, beauty remains a form of control and comfort,' Megan said. Amid President Donald Trump 's tariffs, these are the signs that women are looking to save money on pricey beauty treatments. 'As tariffs begin to impact beauty, prices will shift, but habits will shift as well,' Megan warned. Recession brunette is one of the trends, along with balayage, which is soft, natural highlights, so it doesn't necessitate constant hairstylist visits. Megan believes 'we'll definitely see the lipstick effect come into play,' because 'consumers still want to treat themselves.' During any kind of economic downturn, more and more women begin purchasing lipstick in a bid to reward or treat themselves without breaking the bank. But young women aren't just indulging by buying lipsticks. Megan said they're also purchasing minis and travel sizes of expensive items as well as 'leading the DIY beauty movement.' Young women are using hair glossing kits, press-on nails, lash extensions, self-tanning products, brow lamination kits, and at-home waxing products for salon results without the hefty price tag. Women have been flocking to social media to show off how they do their own lashes at home as they complain about ultra-high salon prices, where lash extensions can cost hundreds a month and thousands a year. Women have been flocking to social media to show off how they do their own lashes at home as they complain about ultra-high salon prices, where lash extensions can cost hundreds a month and thousands a year 'While the costs of goods are rising, consumers will reframe value and view the products they buy not just in terms of price, but in performance, purpose, and practicality,' Megan warned. Megan believes people are going to try more cost-effective beauty techniques, including doing their own hair extensions and spray tans. Young women are buying dupes, not just when it comes to high-end items like bags, but also to try more affordable makeup products. They're flocking to TikTok Shop to buy these inexpensive options when they're not opting for at-home spa days.
CBS News
02-04-2025
- CBS News
Family alleges Plano ISD teacher abused high school student with disability; police investigating
A Plano Independent School District family believes their high school senior, who has a disability, was abused by a teacher. Police are investigating. Lestia Nelson said a few years ago her daughter, Saniyah was diagnosed with a rare genetic disorder called GRIN syndrome. "She's totally disabled," she said. "She needs help with personal care, feeding, transferring, diapering, everything." Nelson said earlier this year, she started noticing things that would concern her when her daughter would arrive home from school. "When she would get home she would have a horrible diaper rash that would be bleeding," she said. "I asked them about it, asked them if they could change her more, and it was a struggle. Also, with the feeding, they put her on a liquid diet without notifying me so Saniyah lost 10-15 pounds." Nelson said she asked her daughter if she could put a recording device in her backpack. "She said yes, so I put an audio recorder in her book bag and just recorded," she said. On January 8, she heard Saniyah crying. "I know that Saniyah doesn't just cry," she said. She took her daughter to a doctor who documented a "decreased range of motion" in her neck. Nelson said her daughter has not returned to school since. She told CBS News Texas she asked Plano ISD to send her the video from that day and just received it last week. A teacher's actions in the video greatly concerned her. "While she was doing something, she elbowed her and pushed her head down and then because Saniyah's head went down, she choked her to pick her up and Saniyah started crying," Nelson said. "I saw that she bent her fingers backward." "It's really difficult to watch the video more than once but each time we do look at it we do find something else that was wrong," Alvin Nelson said. On social media, Lestia Nelson documented all of her concerns. In a statement to CBS News Texas, a spokesperson for Plano ISD said: Plano police confirm they're investigating. Lestia Nelson believes there needs to be more accountability and wants to see criminal charges. "I'm a fighter and I'm going to fight for Sanaya until everything is right," she said.
Yahoo
01-04-2025
- Business
- Yahoo
GRIN Therapeutics Receives Priority Medicines (PRIME) Designation from EMA for Radiprodil in the Treatment of GRIN-Related Neurodevelopmental Disorder
Designation highlights continued regulatory progress and recognizes the potential for radiprodil to address the unmet need to a significant extent in GRIN-related neurodevelopment disorder NEW YORK, April 1, 2025 /PRNewswire/ -- GRIN Therapeutics, Inc., a leader in the development of therapies to treat serious neurodevelopmental disorders, today announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to radiprodil, the company's investigational, potent negative allosteric modulator selectively targeting the N-methyl-D-aspartate receptor subtype 2B (NR2B or GluN2B), for the treatment of GRIN-related neurodevelopmental disorder (NDD). This decision follows the recent announcements that radiprodil was awarded Breakthrough Therapy designation for the treatment of seizures associated with GRIN-related NDD with gain-of-function (GoF) mutations and Orphan Drug designation for the treatment of GRIN-related NDD by the U.S. Food and Drug Administration (FDA) in February and March 2025, respectively. The company remains on track to initiate a global pivotal Phase 3 clinical trial for radiprodil for the treatment of GRIN-related NDD in mid-2025. "The decision by the EMA to award PRIME designation highlights the global unmet need for treatment options for individuals suffering from GRIN-related NDD and our efforts to develop the first selectively targeted treatment for this condition," said Michael A. Panzara, MD, MPH, Chief Medical Officer at Neurvati Neurosciences and GRIN Therapeutics. "We look forward to continuing to work with global regulatory authorities and the patient community to achieve this goal." PRIME designation is granted by the EMA in recognition of priority medicines that have demonstrated the potential to target an unmet need to a significant extent. PRIME provides enhanced support for the development of therapeutic candidates in order to help optimize development plans and speed up the evaluation process so medicines can reach patients earlier. This designation provides drug developers with several benefits, including early appointment of the Committee for Medicinal Products for Human Use (CHMP) Rapporteur, which enables discussion regarding preparation of the marketing authorization application (MAA), enhanced interaction and early dialogue with the EMA. GRIN Therapeutics, which is backed by a $200M capital commitment from Blackstone Life Sciences, remains on track to initiate a global Phase 3 pivotal trial for radiprodil in GRIN-related NDD in mid-2025. The Phase 3 trial will aim to evaluate the impact of targeted treatment on core aspects of the disease, including seizures, behavioral abnormalities and functional outcomes. About GRIN-related neurodevelopmental disorder GRIN-related neurodevelopmental disorder is a family of rare, genetically defined pediatric neurodevelopmental disorders caused by mutations in GRIN genes. While symptoms of GRIN-related neurodevelopmental disorder can present as early as infancy, a diagnosis is often not confirmed until age two or later when a child fails to reach developmental milestones. Individuals may experience developmental delay, intellectual disabilities, epilepsy, muscular hypotonia, movement disorders, spasticity, feeding difficulties and behavioral problems. There are currently no approved therapies for GRIN-related neurodevelopmental disorder. About Radiprodil Radiprodil is an investigational, selective and potent negative allosteric modulator of the N-methyl-D-aspartate (NMDA) receptor subtype 2B (NR2B or GluN2B) that has received Breakthrough Therapy designation and Orphan Drug designation from the U.S. Food and Drug Administration (FDA) as well as Priority Medicines (PRIME) designation from the European Medicines Agency (EMA). In in vitro and in vivo preclinical models, radiprodil has been shown to potently and selectively modulate GluN2B. In 2024, data from the Phase 1b Honeycomb study of radiprodil in pediatric patients with GRIN-related neurodevelopmental disorder and confirmed Gain of Function (GoF) mutations showed that patients in the qualifying seizure cohort experienced a median reduction of 86% in countable motor seizure (CMS) frequency compared to baseline, with 5 of 7 patients seeing greater than 50% reduction. Clinicians and caregivers generally assessed patients as improved clinically over the course of the study regardless of the occurrence of seizures as measured by Clinician and Caregiver Global Impressions of Change (CGI-C and CaGI-C) and the Aberrant Behavior Checklist – Community (ABC-C) scales. In addition, the drug appeared to be generally well tolerated. Adverse events most commonly observed were those associated with infections or underlying disease symptoms. Three patients experienced a serious adverse event associated with infection; all were assessed as unrelated to radiprodil. Radiprodil is also being developed for the treatment of tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD). In vitro analysis of brain tissues extracted from both TSC and FCD lesions has shown enhanced GluN2B NMDA expression supporting the potential ability of radiprodil to control seizures in these conditions. RAD-GRIN-201, also known as the Astroscape study, is an ongoing, open-label Phase 1b/2a trial assessing the safety, tolerability, pharmacokinetics (PK), and potential efficacy of radiprodil in participants with TSC or FCD type II. About GRIN Therapeutics GRIN Therapeutics is dedicated to the research and development of precision therapeutics for pediatric neurodevelopmental disorders with the goal of bringing hope to patients and caregivers. Late last year, GRIN Therapeutics reported promising topline data from a Phase 1b/2a clinical trial (the Honeycomb Trial) evaluating radiprodil in GRIN-related neurodevelopmental disorder in patients with GoF variants, leading to the decision to advance to a Phase 3 trial. The company has an additional ongoing clinical trial to evaluate radiprodil for the potential treatment of tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) type II. GRIN Therapeutics is an affiliate of Neurvati Neurosciences, a portfolio company of Blackstone Life Sciences (BXLS). For more information, please visit About Neurvati Neurosciences Neurvati Neurosciences, a portfolio company of Blackstone Life Sciences, identifies and advances the development of high-potential drug candidates across the neuroscience landscape. Neurvati employs a collaborative model that establishes fit-for-purpose affiliate companies, aligning dedicated resources with long-term strategic capital to catalyze innovative treatment options in areas of unmet need. Neurvati's team of experienced operators and drug developers seeks opportunities to challenge current treatment paradigms and make a difference for patients suffering from a wide range of neurological and psychiatric disorders. For more information, please visit About Blackstone Life Sciences Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within key life science sectors. By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines and medical technologies that improve patients' lives and currently has more than $12 billion in assets under management. Corporate Contact Elliott Ruiz, MBA+1 View original content: SOURCE GRIN Therapeutics Inc. Sign in to access your portfolio
